In the largest study of its kind to date, a team of investigators at the Feinstein Institutes for Medical Research analyzed the electronic health records of 5,449 hospitalized COVID-19 patients between March 1, 2020, and April 5, 2020 and determined that 36.6 % (1,993 patients) developed AKI.
Among patients with AKI at the study's conclusion, 39.1 % (780 out of 1,993) were still hospitalized.
AKI is a sudden episode of kidney failure or damage, preventing waste from being filtered within the body and can often lead to death.
Most cases developed early in a patient's hospitalisation, with 37.3% either arriving with AKI or developing it within 24 hours.
The number of patients requiring dialytic support at some point during their hospitalization was 285 or 5.2% of all patients, representing 14.3% of those with AKI. The link between respiratory failure and AKI was substantial.
Among patients who required mechanical ventilation, 89.9% (1,068/1,190) developed AKI, compared to 21.7% (925/4259) in non-ventilated patients.
Among patients who required mechanical ventilation, 23.2% (276 of 1,190) developed AKI and required dialysis therapy, compared to 0.2% (9 of 4,259) in non-ventilated patients.
In comparison to data from China, respiratory disease severity appeared to be less in China, as 13.4% of the Chinese patients required mechanical ventilation compared to 21.8% of the patients in the US study.
The study also revealed risk factors for developing AKI, including age, diabetes mellitus and cardiovascular disease, hypertension, and need for ventilation and vasopressor medications. Researchers also found those of the Black race were at increased risk for developing AKI.
Future studies will look to better understand the causes of AKI and patient outcomes.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement